Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan

Table 2 Demographic and substance use variables associated with HCV/HIV co-infection and HCV mono-infection in backward stepwise multinomial regression analysis

	AOR	95%CI
HCV and HIV co-infection
Shared syringes^a	27.72	13.30-57.76
Number of MMTP enrollments (per time increase)	2.28	1.33-3.90
Number of times incarcerated (per time increase)	2.01	1.71-2.37
Smoking amphetamine^a	0.44	0.25-0.76
HCV mono-infection
Number of times incarcerated (per time increase)	1.77	1.52-2.06
Length of drug injection (per year increase)	1.04	1.01-1.07
Smoking amphetamine^a	0.49	0.32-0.75
Positive amphetamine urine drug screen^b	0.61	0.40-0.93

Reference is HCV/HIV-seronegative cases.
AOR, adjusted odds ratio. CI, confidence interval. HCV, hepatitis C virus. HIV, human immunodeficiency virus. MMTP, methadone maintenance treatment program.
^a During the 6 months before enrollment in the MMTP.
^b At the time of enrollment in the MMTP.

ISSN: 1471-2458